Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY25 results · Jan–Mar 2025
Suven Life Sciences reported revenue from operations of ₹1.47 crore (down 38.5% from Q4 FY24) and net loss of ₹43.94 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.47 | 2.39 | −38.5% | 1.61 | −8.9% |
| Other income | 1.22 | 4.28 | −71.5% | 1.63 | −25.0% |
| Total income | 2.69 | 6.67 | −59.7% | 3.24 | −17.0% |
| Profit before tax | (43.94) | (27.54) | Loss widened | (39.12) | Loss widened |
| Net profit for the period | (43.94) | (26.54) | Loss widened | (39.12) | Loss widened |
| EPS, basic (₹) | (2.02) | (1.22) | Loss widened | (1.79) | Loss widened |
| Net margin (%) | -2995.6 | -1112.7 | -2429.8 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.47 | 2.39 | −38.5% | 1.61 | −8.9% |
| Other income | 1.19 | 4.28 | −72.2% | 1.57 | −24.1% |
| Total income | 2.66 | 6.67 | −60.1% | 3.18 | −16.4% |
| Profit before tax | (15.07) | (4.13) | Loss widened | (13.27) | Loss widened |
| Net profit for the period | (15.07) | (3.12) | Loss widened | (13.27) | Loss widened |
| EPS, basic (₹) | (0.69) | (0.14) | Loss widened | (0.61) | Loss widened |
| Net margin (%) | -1027.3 | -131.0 | -824.4 |
Consolidated
- Filed with BSE
- 13 May 2025, 18:02 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2025, 18:02 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE